 TEL AVIV, Israel, Dec. 17, 2020 PRNewswire -- Galmed Pharmaceuticals Ltd. Nasdaq: GLMD Galmed or the Company, a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase 3... 